Key points are not available for this paper at this time.
Sacituzumab-govitecan (Sgov) is a new antibody-drug conjugate recently approved for metastatic triple negative breast cancer (mTNBC), so there are still few data published in the real-world setting.
Madroñal et al. (Thu,) studied this question.